Meanwhile, the tumor-inhibitory effects and cytotoxic immune infiltration after aPD-L1 immunotherapy in BMFsPD-L1-KO-rich tumors consistently recovered to desirable levels, further validating the potential of targeting at the overexpressed PD-L1 in BMFs to overcome aPD-L1 therapy resistance. This evidence concerns the gene CD274 and neoplasm.